Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(3.93)
# 408
Out of 4,829 analysts
10
Total ratings
40%
Success rate
23.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Maintains: Buy | $15 → $20 | $9.10 | +119.78% | 3 | Mar 18, 2025 | |
| VRNA Verona Pharma | Initiates: Buy | $68 | $67.53 | +0.70% | 1 | Jan 10, 2025 | |
| CING Cingulate | Initiates: Buy | $12 | $3.98 | +201.51% | 1 | Jan 10, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $0.78 | +801.13% | 1 | Jan 10, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 | $1.92 | +264.58% | 2 | Dec 24, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $8.82 | +228.80% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.47 | +580.27% | 1 | Dec 5, 2024 |
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $9.10
Upside: +119.78%
Verona Pharma
Jan 10, 2025
Initiates: Buy
Price Target: $68
Current: $67.53
Upside: +0.70%
Cingulate
Jan 10, 2025
Initiates: Buy
Price Target: $12
Current: $3.98
Upside: +201.51%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $0.78
Upside: +801.13%
Gain Therapeutics
Dec 24, 2024
Maintains: Buy
Price Target: $7
Current: $1.92
Upside: +264.58%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $8.82
Upside: +228.80%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.47
Upside: +580.27%